Precipio Launches its Proprietary HemeScreen AML (Acute Myeloid Leukemia) Molecular Panel - Seite 2

To the best of our knowledge, Precipio is the first and only laboratory that can provide same day results that meet the clinical turnaround time requirements for this disease, helping physicians provide immediate and critical care to their patients.

Economic Advantages of HemeScreen

The benefits of HemeScreen AML are first and foremost to ensure that clinicians and their patients receive rapid results critical to their battle with the disease; however, they go beyond the impact to patient care. As part of the HemeScreen product line of assays, HemeScreen AML joins our current HemeScreen MPN panel which includes the important JAK2, MPL and CALR genes. Laboratories and physician office labs (POLs) can run the test in house and generate revenue otherwise foregone by sending these tests out.

¹ www.cancer.net

This also means that laboratories (whether reference laboratories or physician office labs) who have adopted the HemeScreen platform, may now add this additional panel to their existing testing menu with no additional capital investment.

Furthermore, the panel is designed to test as few as one or two patient samples, while still providing the laboratory with attractive economics. Laboratories using HemeScreen no longer need to “hold” patient samples in order to fill a batch and satisfy economic requirements, impacting patient care. With the HemeScreen AML panel, laboratories can test that patient sample individually, on the same day the sample is received, providing both immediate clinical value while maintaining attractive economics.

Precipio will offer the test in two methods:

1. As a set of reagents
2. As a pre-plated assay (eliminating the majority of tech time and labor for sample prep)

For more information on this test, please email us at [e-mail]; contact us at 203.787.7888 or visit our website at www.precipiodx.com/hemescreen.

“For years laboratories have been forced to choose economics over patient care in order to provide a service that is financially sustainable. HemeScreen removes the need to make that choice,” said Ilan Danieli, Precipio’s CEO. “I’m proud of our R&D team which continues to develop these groundbreaking technological tools, routed in the advancement of patient care. Making these panels available not only to our oncology customers in our CLIA laboratory, but also for broad use through our reference labs and POL customers, ensures a broad impact on tens of thousands of patient’s lives.”